BackRVL Pharmaceuticals plc Overview

RVL Pharmaceuticals plc Common Stock

Latest common stock for RVLP: $990K.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$994000.00
18.90% YoYΔ $158000.00 vs prior year quarter

Peer trimmed avg / median

Loading

RVL Pharmaceuticals plc Common Stock History

Loading

RVL Pharmaceuticals plc vs. peers: Common Stock Comparison

Loading

RVL Pharmaceuticals plc Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

RVL Pharmaceuticals plc (RVLP) FAQ

The latest common stock for RVLP is $990K as of June 2023. That compares with $840K in the prior-year period — up 18.9% year over year. Investors often review this figure alongside RVL Pharmaceuticals plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, RVLP's common stock moved from $840K to $990K — a 18.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in RVL Pharmaceuticals plc's operating scale or balance-sheet position.

A common stock figure of $990K for RVLP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RVLP's common stock ($990K), review year-over-year change from $840K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack RVL Pharmaceuticals plc's common stock against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.